Scientific Advice from EMA Committee for Medicinal Products for Human Use Requested...
Clinical Trial Shows Substantially Improved Bioavailiability...
CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...
CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...
CALGARY, Alberta, June 06, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...
CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...
Bridging Pharmacokinetics Study Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program...
Patent supporting Autosomal Dominant Polycystic Kidney Disease Granted – XRx-008 Program...
● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics...
Compositions and Methods for Enhancing Anti-Viral Therapies...